COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,254 Articles (22,733 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 1082: Articles 10811-10820  | Next

First and Second Wave Dynamics of Emergency Department Utilization during the COVID-19 Pandemic: a retrospective study
Dijk, R., Plaum, P., Tummers, S., van Osch, F., Barten, D., Latten, G.
10.1101/2021.12.09.21267520 — Posted: 2021-12-09
Structural Insights of SARS-CoV-2 Spike Protein from Delta and Omicron Variants
Sadek, A., Zaha, D., Ahmed, M. S.
10.1101/2021.12.08.471777 — Posted: 2021-12-09
A Graph Convolutional Network-based screening strategy for rapid identification of SARS-CoV-2 cell-entry inhibitors
Gao, P., Xu, M., Zhang, Q., Chen, C., Guo, H., Ye, Y., Zheng, W., Shen, M.
10.1101/2021.12.08.471787 — Posted: 2021-12-09
Mutations in the spike RBD of SARS-CoV-2 omicron variant may increase infectivity without dramatically altering the efficacy of current multi-dosage vaccinations
Li, B., Luo, X., McAndrews, K. M., Kalluri, R.
10.1101/2021.12.08.471688 — Posted: 2021-12-09
Deep Mutational Engineering of broadly-neutralizing and picomolar affinity nanobodies to accommodate SARS-CoV-1 & 2 antigenic polymorphism
Laroche, A., Orsini Delgado, M. L., Cuniasse, P., Dubois, S., Sierocki, R., Gallais, F., Debroas, S., Bellanger, L., Simon, S., Maillere, B., Nozach, H.
10.1101/2021.12.07.471597 — Posted: 2021-12-09
Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster model
Climax, J., Hamza, M., Lafferty, A., Guilfoyle, K., van Amerongen, G., Stadler, K., Wohlsein, P., Baumgärtner, W., Weissbach, M., Coughlan, D.
10.1101/2021.12.07.471588 — Posted: 2021-12-09
Combinatorial mRNA vaccination enhances protection against SARS-CoV-2 delta variant
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., Liu, Y., Hazell, N. C., Sun, J., Soong, L., Shi, P.-Y., Wang, T., Sun, J., Weissman, D., Weaver, S. C., Plante, K. S., Hu, H.
10.1101/2021.12.08.471664 — Posted: 2021-12-09
B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
Cao, Y. R., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., Wang, J., Wang, Y., Niu, X., Yang, S., Liang, H., Sun, H., Li, T., Yu, Y., Cui, Q., Liu, S., Yang, X., Du, S., Zhang, Z., Hao, X., Shao, F., Jin, R., Wang, X., Xiao, J., Wang, Y., Xie, X. S.
10.1101/2021.12.07.470392 — Posted: 2021-12-09
Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination
Newell, K. L., Waldran, M. J., Thomas, S. J., Endy, T. P., Waickman, A. T.
10.1101/2021.12.08.471684 — Posted: 2021-12-09
Predictive profiling of SARS-CoV-2 variants by deep mutational learning
Taft, J. M., Weber, C. R., Gao, B., Ehling, R. A., Han, J., Frei, L., Metcalfe, S. W., Yermanos, A., Kelton, W., Reddy, S. T.
10.1101/2021.12.07.471580 — Posted: 2021-12-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).